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MARKO PEĆINA, MISLAV JELIĆ, ALAN IVKOVIĆ, DAMIR HUDETZ 
Gene therapy applications in orthopaedics. 
Dear Editor, 
 
With great interest and enthusiasm, we read the article „Orthopaedic applications 
of gene therapy“ [1]. The authors should be congratulated for their concise yet very 
thorough and excellent coverage of the gene application in orthopaedics. However, it is 
our opinion that articular cartilage deserved more attention in the mentioned review. First 
of all we think that even subchapter title “Cartilage repair” should be expanded to 
“Cartilage repair and regeneration” especially because authors did mention “stimulation 
of cartilage regeneration” which would imply the possibility to induce intrinsic healing of 
the damaged cartilage by hyaline cartilage formation. When treating localized cartilage 
defects we should ask ourselves: what kind of new tissue formation inside the defect do 
we want to induce? Idealistically we aim for articular cartilage regeneration, not repair, 
which would mean a hyaline cartilage, not fibrocartilage formation. Treatment options 
published in the literature could be roughly divided into two concepts – reparative and 
restorative. The end result of the first concept is fibrocartilage, and microfracture 
technique is the most popular representative. However, restorative concept aims for 
hyaline cartilage implantation/formation and includes implantation of osteochondral 
plugs with perfectly organized cartilage and matrix and/or cell therapy, namely 
autologous chondrocyte transplantation. Anabolic factors including members of the TGF-
beta superfamily, such as BMPs have proven their potential to stimulate chondrogenesis 
and synthesis of cartilage-specific matrix components in animal models [2,3]. However, 
those proteins have short half-lives and it is difficult to maintain adequate in situ 
concentrations necessary for their proper functioning. Furthermore, many proteins act 
intracellulary and because cells cannot normally import these proteins, they cannot be 
used in soluble forms. These problems are the reason why gene therapy has acquired so 
much attention lately. The transfer of the respective genes into the joint, possibly in 
combination with the supply of chondroprogenitor cells, might be an elegant method to 
achieve a sustained delivery of such therapeutic factors at the required location in vivo 
[4]. Pascher et al.[5] developed a novel ex vivo method by using coagulated bone marrow 
aspirate as a mean of gene delivery to cartilage. Vector-seeded and cell-seeded bone 
marrow clots (“gene plugs”) were found to maintain their structural integrity following 
extensive culture and maintained transgenic expression for several weeks.  
Therefore, we conclude that there is a huge potential for new tissue formation by 
gene therapy trandsuction of cells of different origin. Cells originating subchondraly, in 
combination with gene therapy, may form tissue of higher quality when compared to 
classical microfracture technique. On the other hand, hyaline cartilage formation by gene 
therapy induction in combination with cell implantation (possibly on biodegradable 
scaffolds) might be the answer to the current limitations of cartilage treatment modalities, 
and may provide permanent solution for the patients. Many animal studies are currently 
investigating the gene therapy induced cartilage regeneration of chondral and 
osteochondral defects, some of which are expected to develop into clinical trials and give 
answers to these open issues. 
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